Please login to the form below

Not currently logged in
Email:
Password:

Lu AE58054

This page shows the latest Lu AE58054 news and features for those working in and with pharma, biotech and healthcare.

Lundbeck trial failure dashes hopes in Alzheimer's once again

Lundbeck trial failure dashes hopes in Alzheimer's once again

Idalopirdine (Lu AE58054) appeared to be safe and showed evidence of "weak efficacy" in the phase III STARSHINE study, which enrolled patients with mild to moderate Alzheimer's.

Latest news

More from news
Approximately 1 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    The first phase III study in patients with mild-to-moderate Alzheimer's disease will assess Lu AE58054 as an adjunct treatment to donepezil. ... The Lu AE58054 deal comes out of an already successful relationship between Lundbeck and Otsuka.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anthill Agency

Anthill is a specialist digital agency and a strategic partner for life science companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics